Vaccibody
Oslo Research Park
Gaustadalléen 21
Oslo
0349
Website: http://www.vaccibody.com/
Email: info@vaccibody.com
11 articles with Vaccibody
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now. -
Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development
11/23/2021
Vaccibody becomes Nykode Therapeutics — a new name and identity, including logo, colors and website, to signify a new phase of growth and development.
-
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.
-
Vaccibody AS & Nektar Therapeutics Announce 1st Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head & Neck
8/12/2020
Vaccibody AS and Nektar Therapeutics announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin, Nektar's CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck.
-
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
4/1/2019
Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist
-
PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS).
-
PharmaJet And Vaccibody Collaborate On HPV Vaccine Development
10/25/2016
-
Vaccibody As Announces Vaccination Of First Patient In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
9/14/2015
-
Vaccibody Appoints Martin Bonde As CEO
6/30/2015
-
Cobra Biologics Ltd. and Vaccibody Sign Agreement to Manufacture DNA Vaccine
5/14/2013
-
Vaccibody Receives Euros 2 Million to Develop Therapeutic Cervical Cancer Vaccine
11/12/2012